Skip to main content
OpenTrials

Clinical trial condition

Non-Muscle Invasive Bladder Neoplasms

Explore clinical trials studying Non-Muscle Invasive Bladder Neoplasms. Study availability and eligibility vary by location and protocol.

195 public trials 69 recruiting studies
Refine in advanced search Browse all conditions

Non-Muscle Invasive Bladder Neoplasms trial results

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • The Kirklin Clinic of UAB Hospital Birmingham, Alabama, United States
  • UAB Infusion Therapy Extended Care Clinic (ECC) Birmingham, Alabama, United States
  • The University of Alabama at Birmingham Investigation Drug Services Pharmacy Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
View all 68 locations
View Trial Details
Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677

Conditions
Carcinoma, FGFR Gene Alterations, FGFR Gene Amplification, +18 more
Locations
  • Urology Centers of Alabama Homewood, Alabama, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • Tri Valley Urology - Murrieta Murrieta, California, United States
  • Eisenhower Medical Associates Rancho Mirage, California, United States
View all 46 locations
View Trial Details
Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • Michael G Oefelein Clinical Trials ( Site 0053) Bakersfield, California, United States
  • Moffitt Cancer Center ( Site 0057) Tampa, Florida, United States
  • Northwestern University ( Site 0051) Chicago, Illinois, United States
  • Johns Hopkins University ( Site 0055) Baltimore, Maryland, United States
View all 13 locations
View Trial Details
Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Academic Urology and Urogynecology of Arizona Sun City, Arizona, United States
  • UCLA Los Angeles, California, United States
  • Colorado Clinical Research Lakewood, Colorado, United States
  • Georgia Urology Atlanta, Georgia, United States
View all 110 locations
View Trial Details
Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

NCT07309445

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
View all 13 locations
View Trial Details
Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Arkansas Urology Little Rock, Arkansas, United States
  • Genesis Research LLC Los Alamitos, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
View all 193 locations
View Trial Details
Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +13 more
Locations
  • Michael G Oefelein Clinical Trials ( Site 0138) Bakersfield, California, United States
  • Genesis Research, LLC ( Site 0141) Los Alamitos, California, United States
  • USC Norris Comprehensive Cancer Center ( Site 0123) Los Angeles, California, United States
  • Genesis Healthcare-Torrance ( Site 0140) Torrance, California, United States
View all 89 locations
View Trial Details
Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
View all 58 locations
View Trial Details

Related conditions